{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field f602ebd0-2784-4fd2-a18d-726b297eb83d --><h2>Erythromycin</h2><!-- end field f602ebd0-2784-4fd2-a18d-726b297eb83d -->","summary":"","htmlStringContent":"<!-- begin item 9b2fd258-137d-417d-a612-404d4253061e --><!-- begin field c51d86c0-0227-4f5f-af79-acf445214f72 --><ul><li>Clarithromycin is preferred and better tolerated than erythromycin, but nausea, vomiting, or diarrhoea can sometimes occur with both drugs. Erythromycin is preferred in women who are pregnant or breastfeeding.<ul></ul></li></ul><!-- end field c51d86c0-0227-4f5f-af79-acf445214f72 --><!-- end item 9b2fd258-137d-417d-a612-404d4253061e -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2e5d3491-b0cc-5735-8187-9e0498aac9bb","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 563734f4-f010-477d-972b-d881e5895428 --><h3>What are the contraindications and cautions for erythromycin?</h3><!-- end field 563734f4-f010-477d-972b-d881e5895428 -->","summary":"","htmlStringContent":"<!-- begin item 5e4f14e3-7cb2-4912-a458-cb4014285e4a --><!-- begin field 17668005-7014-4b0b-b909-784cfa21bb71 --><ul><li><strong>Do not prescribe</strong> <strong>erythromycin to people with </strong><ul><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution in people with:</strong><ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with these drugs.</li><li>Renal impairment:<ul><li>For erythromycin — give a maximum of 1.5 g daily in severe renal impairment due to the risk of ototoxicity.</li></ul></li><li>Myasthenia gravis — macrolide antibiotics may aggravate the weakness of people with myasthenia gravis.</li><li>Conditions that predispose to QT interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">MHRA, 2020</a>]</p><!-- end field 17668005-7014-4b0b-b909-784cfa21bb71 --><!-- end item 5e4f14e3-7cb2-4912-a458-cb4014285e4a -->","subChapters":[]},{"id":"9806ae4d-bfcd-5030-b8c0-cc42387dc983","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a27be3a0-eca0-4d42-a23e-d9504b550cb2 --><h3>What are the drug interactions of erythromycin?</h3><!-- end field a27be3a0-eca0-4d42-a23e-d9504b550cb2 -->","summary":"","htmlStringContent":"<!-- begin item 4b635a84-1a0a-4f07-9ae3-887de795a07b --><!-- begin field 234f78bd-7a4d-4bb8-915f-c0cd6a7574fb --><ul><li><strong>Drug interactions that may occur with erythromycin include:</strong><ul><li><strong>Theophylline </strong>— erythromycin increases plasma concentrations of theophylline, and theophylline may also reduce absorption of oral erythromycin.</li><li><strong>Carbamazepine </strong>— macrolides inhibit the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin.</li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if a macrolide is taken with simvastatin or atorvastatin.<ul><li>For simvastatin — concurrent use with erythromycin is contraindicated as simvastatin is extensively metabolized by CYP3A4. If treatment with erythromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin, avoid concurrent use with erythromycin, as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, an interaction with erythromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Drugs that prolong the QT interval </strong>(such as haloperidol, sotalol, terfenadine, and pimozide) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are not required during or after courses of erythromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>. </li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">MHRA, 2020</a>]</p><!-- end field 234f78bd-7a4d-4bb8-915f-c0cd6a7574fb --><!-- end item 4b635a84-1a0a-4f07-9ae3-887de795a07b -->","subChapters":[]},{"id":"7fda0a28-aafe-5eef-9c4c-a47793601e7e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e3a85874-cfd7-4531-a522-0445e7e5e7a6 --><h3>What are the adverse effects of erythromycin?</h3><!-- end field e3a85874-cfd7-4531-a522-0445e7e5e7a6 -->","summary":"","htmlStringContent":"<!-- begin item f6c97656-6fe7-4b97-a43f-b0e458880fc7 --><!-- begin field bcc4d644-40ee-478b-8c95-c0ca897555d0 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides, and are more common with erythromycin than with clarithromycin.</li><li><strong>Consider pseudomembranous colitis</strong> if a person develops severe diarrhoea during or after treatment with a macrolide.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with macrolides.</li><li><strong>Hepatotoxicity</strong> (including cholestatic jaundice) and rash have been reported following treatment with macrolides.</li><li><strong>Reversible hearing loss</strong> (sometimes with tinnitus) can occur after large doses of clarithromycin (1–2 g) or erythromycin (more than 4g).</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field bcc4d644-40ee-478b-8c95-c0ca897555d0 --><!-- end item f6c97656-6fe7-4b97-a43f-b0e458880fc7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}